Effects of sacubitril valsartan combined with Songling Xuemaikang capsules for elderly patients with hy-pertension and chronic heart failure
Objective To explore the clinical effect of the combination of sacubitril valsartan and Songling Xuemaikang capsules for elderly patients with hypertension and chronic heart failure(HF).Methods A retrospective study was conducted on 106 elderly patients(aged ≥ 60 years)with hypertension and chronic HF admitted to our hospital from January 1,2021 to March 1,2023.All patients have received routine treatment for hypertension and chronic HF,as well as treatment with sacubitril and valsartan.According to whether the patient received additional treatment with Songling Xuemaikang capsules(1.5 g each time,3 times a day,orally),they were divided into two groups:the sacubitril valsartan combined with Songling Xuemaikang treatment group(n=39)and the sacubitril valsartan group(n=67).Two groups of patients were followed up for 6 months,during which they received corresponding treatment.Baseline characteristics of two groups of patients were collected and compared their 24-hour mean systolic blood pressure levels,24-hour mean diastolic blood pressure levels,heart rate levels,serumn low-density lipoprotein cholesterol(LDL-C)levels,triglyceride levels(TG),homocysteine levels(Hcy),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),left ventricular posterior wall thickness(LVPWT),and N-terminal Pro Brain Natriuretic Pep-tide(NT-proBNP).Evaluate whether there are differences in adverse reactions between the two groups during treatment period.Results The 24-hour mean systolic blood pressure level and 24-hour mean diastolic blood pres-sure in both groups decreased significantly after treatment(t=6.06、8.95、4.33、5.19,P＜0.01),and the sacubitril valsartan and Songling Xuemaikang treatment group showed a more significant decrease compared to the sacubitril valsartan group(t=6.92、5.18,P＜0.05).Both groups had no effect on heart rate after treatment(P＞0.05).After treatment,LDL-C and TG levels decreased in both groups(t=2.33、1.87、3.01、2.92,P＜0.05),and the sacubitril valsartan and Songling Xuemaikang treatment group showed a more significant decrease compared to the sacubitril valsartan group(t=2.10、2.46,P＜0.05).After treatment,both groups showed improvement in Hcy(t=2.62、1.90,P＜0.05),and the sacubitril valsartan and Songling Xuemaikang treatment group showed a more significant decrease compared to the sacubitril valsartan group(t=2.08,P＜0.05).Both groups showed a significant increase in LVEF af-ter treatment(t=6.08、5.37,P＜0.01),and the improvement effect of the sacubitril valsartan and Songling Xue-maikang treatment group was slightly significant(t=5.67,P=0.04).After treatment,LVEDD,LVESD and LVPWT were significantly reduced in both groups(t=5.39、5.27、3.86、3.17、1.58、1.21,P＜0.05),but there was no statisti-cally significant difference between the two groups(P＞0.05).After treatment,both groups showed a significant de-crease in NT-proBNP(t=3.15、2.97,P＜0.05),but there was no statistically significant difference between the two groups(P＞0.05).During the 6-month follow-up period,there was no statistically significant difference in the oc-currence of adverse reactions(P＞0.05)between the sacubitril valsartan and Songling Xuemaikang treatment group and the sacubitril valsartan group.Conclusion In elderly patients with hypertension and chronic HF,the combi-nation of sacubitril valsartan with Songling XuemaiKang can significantly reduce blood pressure and lipid levels,improve LVEF,and do not increase risks of adverse reactions during follow-up.It is worth promoting in clinical practice.
Song Ling Xue Mai Kang Jiao NangAgedHypertensionHeart failure
万方数据
维普
